SLC29A3: A Potential Drug Target (G55315)

Target Name: SLC29A3

NCBI ID: G55315

SLC29A3

SLC29A3: A Potential Drug Target

SLC29A3, also known as equilibrative nucleoside transporter member 3, is a protein that is expressed in various tissues throughout the body. It is a member of the SLC29 family of transporters, which are known for their ability to transport a wide variety of nucleosides and nucleotides across cell membranes. One of the unique features of SLC29A3 is its expression pattern, which is highly dependent on the presence of bound nucleosides.

SLC29A3 is a 29kDa protein that is composed of 115 amino acid residues. It has a single transmembrane region and a unique ATP-binding site that is located at its cytoplasmic side. SLC29A3 is primarily localized to the endoplasmic reticulum (ER), where it is involved in the transport of nucleosides and nucleotides across the membrane.

SLC29A3 has been identified as a potential drug target due to its involvement in various cellular processes, including DNA replication, cell signaling, and neurotransmission. One of the key reasons for its potential as a drug target is its high degree of expression and stability, which allows for efficient production of recombinant proteins for research and clinical development.

SLC29A3 has been shown to play a critical role in the replication of DNA in various cell types. For example, SLC29A3 has been shown to be involved in the replication of DNA in T cells, a type of white blood cell that plays a critical role in cell signaling and immune responses. In addition, SLC29A3 has been shown to be involved in the regulation of DNA replication in various cancer cells, which could make it an attractive target for cancer therapies.

SLC29A3 has also been shown to play a critical role in cell signaling and neurotransmission. For example, SLC29A3 has been shown to be involved in the regulation of neurotransmitter release in neurons, which is important for various cellular processes, including mood regulation and learning. In addition, SLC29A3 has been shown to play a critical role in the regulation of ion channels in neurons, which is important for the proper functioning of neurons.

In addition to its involvement in cellular processes, SLC29A3 has also been shown to have potential as a drug target due to its unique structure and its ability to interact with small molecules. SLC29A3 is a type of transporter that is known for its ATP-binding site, which allows it to interact with small molecules that are able to bind to its ATP-binding site. This could make it an attractive target for small molecule inhibitors, which could be used to treat a wide range of diseases.

Overall, SLC29A3 is a protein that has the potential to be a drug target due to its involvement in various cellular processes and its unique structure. Further research is needed to fully understand the role of SLC29A3 in cellular processes and its potential as a drug target.

Protein Name: Solute Carrier Family 29 Member 3

Functions: Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). Mediates transport of adenine, adenosine and uridine, as well as several nucleoside analog drugs, such as anticancer and antiviral agents, including cladribine, cordycepin, tubercidin and AZT. Does not transport hypoxanthine

The "SLC29A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC29A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets